Abbott Laboratories Corporation

Mark W Holladay

Nan-Horng Lin

Keith Brian Ryther

William A Carroll

Yun He

Hao Bai

Henry Q Zhang

Irene I Drizin

James P Sullivan

Yihong Li

James T Wasicak

David S Garvey

Michael J Dart

Richard L Elliott

John K Lynch

David E Gunn, Jr

Lin Yi

Yat Sun Or

Philip R Kym

Robert J Altenbach

Michael E Kort

Melwyn A Abreo

Alex M Nadzan

James F Kerwin

Paul P Ehrlich

Hana A Kopecka

Kazumi Shiosaki

Stephen P Arneric

Youe-Kong Shue

Teodozyj Kolasa

Jerome F Daanen

Arturo Perez-Medrano

Michael D Tufano

Jeffrey J Rohde

Murali Gopalakrishnan

Michael D Meyer

Paul D May

John Y Chung

Peggy Huang

Jorge D Brioni

Hugh N Nellans

Robert J Gregg

Suzanne A Lebold

Chun W Lin

Michael J Bennett

Yiyuan Chen

Albert Khilevich

Mark S Brodie

John F Kincaid

Rui Tang

Potassium channel openers

Tricyclic dihydropyrimidine potassium channel openers

Imidazoles and related compounds as &agr;1A agonists

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

3-Pyridyl enantiomers and their use as analgesics

The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula I with the variables defined in the specification are also described.

3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling

Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

Furopyridine, thienopyridine pyrrolopyridine useful in controlling

Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.

3-pyridyloxymethyl heterocyclic ether compounds useful in controlling

Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.

Heterocyclic ether compounds useful in controlling neurotransmitter

7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula ##STR1## wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.

7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in

Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.

Growing community of inventors

Libertyville, IL, United States of America

Mark W Holladay